Ty Gluckman, M.D., says missed lipid tests and clinical inertia, not prior authorization, are now the main barriers to reaching LDL goals.
News|Articles|October 1, 2004
Rofecoxib voluntarily withdrawn from market due to cardiovascular risk
Rofecoxib voluntarily withdrawn from market due to cardiovascular risk
Advertisement
Advertisement
Related to this article
AI analyzes single-lead ECGs from sleep studies to predict atrial fibrillation, heart failure, and mortality risk, enabling scalable cardiovascular disease screening.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Updated HIV treatment guidelines address payer barriers and add Bixlenvo
2
5 things you should know about the midterms and healthcare
3
What stands in the way of patients with atopic dermatitis getting prescription medication? Here are some possibilities
4
Narcolepsy type 1 drives 5-fold higher costs in first year after diagnosis
5